aDepartment of Hematology, Osaka International Cancer Institute, Osaka, JapanbDivision of Hematology/Oncology, Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
Checking for direct PDF access through Ovid
Purpose of reviewAllogeneic hematopoietic stem cell transplantation (allo-HSCT) has become one of the standard treatment for hematological diseases. Although the clinical outcome has improved significantly during the last decades, the morbidity and mortality after allo-HSCT are still obstacles to cure. Out of major morbidities, opportunistic virus infections such as cytomegalovirus (CMV) infection are important complications, in particular in patients who received human leukocyte antigen-mismatched HSCT. Here, we aim to summarize information about current and future therapeutic options in CMV disease after allo-HSCT.Recent findingsRecently, not only new drugs but also adoptive T-cell therapy are tested in the setting of clinical trials. CMV prophylaxis using letermovir significantly reduced the incidence of CMV disease in comparison to placebo in a phase III clinical trial. Meanwhile, adoptive T-cell therapies which are fully adapted to good manufacturing practice (GMP) conditions are now available. A recent multicenter study in Germany showed a promising result using Streptamer-isolated T-cell therapy.SummaryWith the recent development of CMV-targeted therapy, treatment strategies of CMV infection would be further sophisticated in the near future.Video abstracthttp://links.lww.com/COID/A19.